This suggests that, to maintain weight loss, treatment for obesity should be considered chronic (as in the case of hypertension), rather than as a short course of treatment associated with acute illnesses [9, 55]
Both medications can independently cause gastrointestinal adverse effects, and their concurrent use may compound these issues
Participants received a once-weekly injection of either 4 mg, 9 mg, or 12 mg of retatrutide, or a placebo, for 80 weeks
( NEJM, JAMA, Obesity, Lancet, and others where there is an eye toward the validity of the study.) And, are the results statistically significant
Obesity (Silver Spring, Md.), 31(3), 703715